To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The pandemic has taught us that health is not the exclusive responsibility of only the Union Health Ministry but jointly addressed by various Ministries at the centre and through state governments
Subscribe To Our Newsletter & Stay Updated
